Remarkably, we found that clinically utilized pan-HDAC inhibitors panobinostat and vorinostat synergize with GPX4 inhibitors to induce cell death in all tested lung, melanoma and breast cancer persister cell models but not in parental cells (Fig. 3, A to F and fig. This evidence concerns the gene GPX4 and melanoma.